Want to see XAIR full AI Analyst Report?
XAIR Stock Chart & Stats
$4.97
$0.21(3.97%)
At close: 4:00 PM EDT
$4.97
$0.21(3.97%)
Day’s Range― - ―
52-Week Range$2.05 - $53.20
Previous Close$5.37
Volume15.95K
Average Volume (3M)69.91K
Market Cap
$2.16M
Enterprise Value$15.66M
Total Cash (Recent Filing)$15.22M
Total Debt (Recent Filing)$23.60M
Price to Earnings (P/E)―
Beta-0.20
Next Earnings
Nov 16, 2026EPS Estimate
-3.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-53.60
Shares Outstanding984,407
10 Day Avg. Volume39,966
30 Day Avg. Volume69,911
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)18.70
Price to Sales (P/S)14.92
P/FCF Ratio-5.98
Enterprise Value/Market Cap7.26
Enterprise Value/Revenue2.04
Enterprise Value/Gross Profit48.77
Enterprise Value/Ebitda-0.53
Forecast
1Y Price Target
$10.00Price Target Upside101.21% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.78
Revenue Forecast (FY)$12.70M
Bulls Say, Bears Say
Bulls Say
LungFit PH AdoptionThe record preliminary quarter indicates that hospital adoption of LungFit PH is translating into measurable commercial growth. Continued use of the installed platform can establish a stronger revenue base, improve operating leverage, and support broader adoption over the next several quarters.
Expanded Market AccessBroader GPO access and international distribution increase the number of hospitals that can purchase or deploy LungFit PH. These channels can shorten the path from commercial activity to utilization, strengthen market reach, and provide a durable foundation for future revenue expansion.
Improving Gross MarginA third consecutive quarter of positive gross profit suggests the commercial model is beginning to produce better unit economics, even though profitability remains limited. Further margin improvement would increase the revenue retained from each sale and help reduce the scale required to approach breakeven.
Bears Say
Severe Ongoing LossesExtremely negative net margins show that the current revenue base remains far below the cost structure needed for a sustainable business. Unless revenue scales substantially or expenses decline further, ongoing losses will continue consuming capital and delay any credible path to profitability.
Cash Burn And Thin EquityHeavy operating and free-cash-flow losses require Beyond Air to rely on outside financing to sustain operations and fund commercialization. Combined with a thin equity base, this reduces financial flexibility and leaves the company more exposed if fundraising becomes less available.
Gen II Regulatory UncertaintyThe 2027 revenue outlook includes anticipated Gen II LungFit PH revenue, making the timing of FDA clearance important to the company’s growth plan. A delay would defer commercialization, postpone expected revenue acceleration, and extend the period of losses and external funding dependence.
Beyond Air News
XAIR FAQ
What was Beyond Air Inc’s price range in the past 12 months?
Beyond Air Inc lowest stock price was $2.05 and its highest was $53.20 in the past 12 months.
What is Beyond Air Inc’s market cap?
Beyond Air Inc’s market cap is $2.16M.
When is Beyond Air Inc’s upcoming earnings report date?
Beyond Air Inc’s upcoming earnings report date is Nov 16, 2026 which is in 24 days.
How were Beyond Air Inc’s earnings last quarter?
Beyond Air Inc released its earnings results on Aug 13, 2026. The company reported -$11 earnings per share for the quarter, missing the consensus estimate of -$10.8 by -$0.2.
Is Beyond Air Inc overvalued?
According to Wall Street analysts Beyond Air Inc’s price is currently Undervalued.
Does Beyond Air Inc pay dividends?
Beyond Air Inc does not currently pay dividends.
What is Beyond Air Inc’s EPS estimate?
Beyond Air Inc’s EPS estimate is -3.31.
How many shares outstanding does Beyond Air Inc have?
Beyond Air Inc has 984,407 shares outstanding.
What happened to Beyond Air Inc’s price movement after its last earnings report?
Beyond Air Inc reported an EPS of -$11 in its last earnings report, missing expectations of -$10.8. Following the earnings report the stock price went up 14.38%.
Which hedge fund is a major shareholder of Beyond Air Inc?
Currently, no hedge funds are holding shares in XAIR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Beyond Air Inc
Beyond Air, Inc. functions as a specialized entity involved in both the development of medical devices and biopharmaceutical solutions. A central part of its operations is the LungFit platform, an innovative system that generates and delivers nitric oxide. Within this platform, LungFit PH is currently available, used to address persistent pulmonary hypertension in infants. Furthermore, the company is advancing LungFit PRO, a product intended for various viral lung ailments like community-acquired viral pneumonia (including COVID-19) and bronchiolitis in hospital settings. It is also creating LungFit GO, which aims to treat nontuberculous mycobacteria infections. The organization adopted its current name, Beyond Air, Inc., in June 2019, having previously been known as AIT Therapeutics, Inc. Its headquarters are situated in Garden City, New York.
XAIR Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a constructive, growth-oriented outlook: management strengthened the balance sheet via a financing, secured important commercial partnerships (including a third national GPO), expanded international distribution, and showed improving unit economics (gross margin up to 13%) while reducing R&D spend. The company reaffirmed 2026 guidance and provided an ambitious multi‑year revenue target for 2027 tied to the potential Gen II LungFit PH launch. Key risks highlighted include flat current revenue, ongoing net losses and cash burn, increased other expense, and regulatory timing uncertainty for Gen II approval. On balance, the positives around financing, commercial traction, margin improvement, and a doubled pipeline outweigh the near-term operational and regulatory risks.View all XAIR earnings summariesXAIR Stock 12 Month Forecast
Average Price Target
$10.00
▲(101.21% Upside)
Technical Analysis
Ownership Overview
62.97% Insiders
1.56% Mutual Funds
― Other Institutional Investors
35.04% Public Companies and
Individual Investors